



April 21, 2017

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 5, 2017 to discuss its first quarter 2017 financial results. Management will also provide a brief update on the business.

To access the live call by phone, dial 719-325-2452; the conference ID is 5957421. The call may also be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through May 19, 2017.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FR α -positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease.

ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyła[®], in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyła[®] is a registered trademark of Genentech, a member of the Roche Group.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170421005099/en/>

For Investors

Thrust IR

Monique Allaire, 617-895-9511

monique@thrustir.com

or

For Media

FTI Consulting, Inc.

Robert Stanislaro, 212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

News Provided by Acquire Media